Franklin Street Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.7M Buy
181,638
+2,421
+1% +$521K 2.55% 9
2026
Q1
$39M Sell
179,217
-3,704
-2% -$822K 2.39% 11
2025
Q4
$41.8M Buy
182,921
+4,257
+2% +$970K 2.39% 12
2025
Q3
$41.4M Buy
178,664
+5,580
+3% +$1.14M 2.38% 13
2025
Q2
$32.1M Buy
173,084
+17,405
+11% +$3.23M 1.99% 15
2025
Q1
$32.6M Sell
155,679
-1,896
-1% -$369K 2.3% 9
2024
Q4
$28M Sell
157,575
-16,081
-9% -$2.96M 1.86% 13
2024
Q3
$34.3M Sell
173,656
-6,056
-3% -$1.13M 2.31% 9
2024
Q2
$30.8M Sell
179,712
-9,083
-5% -$1.5M 2.2% 8
2024
Q1
$34.4M Sell
188,795
-2,969
-2% -$512K 2.54% 11
2023
Q4
$29.7M Sell
191,764
-12,268
-6% -$1.79M 2.43% 11
2023
Q3
$30.4M Buy
204,032
+11,478
+6% +$1.68M 2.7% 8
2023
Q2
$25.9M Sell
192,554
-1,889
-1% -$277K 2.2% 16
2023
Q1
$31M Sell
194,443
-35,520
-15% -$5.43M 2.82% 8
2022
Q4
$37.2M Buy
229,963
+12,880
+6% +$1.97M 3.53% 4
2022
Q3
$29.1M Sell
217,083
-37,342
-15% -$5.36M 2.95% 7
2022
Q2
$39M Sell
254,425
-21,213
-8% -$3.24M 3.68% 4
2022
Q1
$44.7M Sell
275,638
-58,353
-17% -$8.48M 3.61% 4
2021
Q4
$45.2M Buy
333,991
+48,826
+17% +$5.77M 3.42% 5
2021
Q3
$30.8M Buy
285,165
+617
+0.2% +$70.5K 2.61% 10
2021
Q2
$32.1M Sell
284,548
-10,134
-3% -$1.14M 2.71% 10
2021
Q1
$31.9M Buy
294,682
+5,365
+2% +$574K 2.96% 9
2020
Q4
$31M Buy
289,317
+4,087
+1% +$393K 3.01% 7
2020
Q3
$25M Buy
285,230
+6,224
+2% +$586K 2.69% 9
2020
Q2
$27.4M Sell
279,006
-7,160
-3% -$630K 3.25% 5
2020
Q1
$21.8M Buy
286,166
+106,456
+59% +$9.07M 3.18% 5
2019
Q4
$15.9M Buy
179,710
+59,830
+50% +$4.97M 1.88% 12
2019
Q3
$9.08M Sell
119,880
-14,113
-11% -$968K 1.15% 38
2019
Q2
$9.74M Sell
133,993
-36,696
-21% -$2.88M 1.25% 33
2019
Q1
$13.8M Sell
170,689
-4,589
-3% -$375K 1.92% 13
2018
Q4
$16.2M Buy
175,278
+595
+0.3% +$52.3K 2.56% 8
2018
Q3
$16.5M Sell
174,683
-5,459
-3% -$518K 2.24% 11
2018
Q2
$16.7M Buy
180,142
+578
+0.3% +$56.4K 2.43% 10
2018
Q1
$17M Buy
179,564
+1,589
+0.9% +$175K 2.55% 9
2017
Q4
$17.2M Sell
177,975
-6,310
-3% -$595K 2.57% 8
2017
Q3
$16.4M Sell
184,285
-30,902
-14% -$2.35M 2.69% 5
2017
Q2
$15.6M Buy
215,187
+23,908
+12% +$1.61M 2.67% 5
2017
Q1
$12.5M Buy
191,279
+18,301
+11% +$1.15M 2.2% 7
2016
Q4
$10.8M Buy
172,978
+8,800
+5% +$537K 1.91% 11
2016
Q3
$10.4M Buy
164,178
+2,666
+2% +$173K 1.88% 9
2016
Q2
$10M Buy
161,512
+16,501
+11% +$1.01M 1.9% 9
2016
Q1
$8.28M Buy
145,011
+12,966
+10% +$723K 1.64% 14
2015
Q4
$7.82M Buy
132,045
+5,381
+4% +$310K 1.54% 13
2015
Q3
$6.89M Buy
126,664
+5,807
+5% +$378K 1.37% 16
2015
Q2
$8.12M Sell
120,857
-188
-0.2% -$12.3K 1.45% 13
2015
Q1
$7.09M Sell
121,045
-6,610
-5% -$399K 1.3% 17
2014
Q4
$8.35M Sell
127,655
-6,785
-5% -$428K 1.59% 13
2014
Q3
$7.76M Sell
134,440
-2,285
-2% -$127K 1.48% 14
2014
Q2
$7.72M Buy
136,725
+8,270
+6% +$434K 1.47% 16
2014
Q1
$6.6M Sell
128,455
-95
-0.1% -$4.8K 1.32% 20
2013
Q4
$6.79M Buy
128,550
+7,363
+6% +$362K 1.37% 17
2013
Q3
$5.42M Buy
121,187
+112,205
+1,249% +$4.97M 1.22% 27
2013
Q2
$372K Buy
+8,982
New +$393K 0.09% 187

Other funds holding ABBV

Franklin Street Advisors's ABBV Position: Q2 2026 in Review

Franklin Street Advisors increased its AbbVie (ABBV) stake by 1.4% in Q2 2026, buying an estimated $521K and bringing the position to 181,638 shares worth $45.7M. The position accounts for 2.55% of the portfolio, ranked #9.

Franklin Street Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 921 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Franklin Street Advisors held 181,638 shares of AbbVie worth $45.7M as of Q2 2026.
  • Franklin Street Advisors bought 2,421 AbbVie shares in Q2 2026, an estimated $521K.
  • AbbVie made up 2.55% of Franklin Street Advisors's portfolio in Q2 2026, its #9 holding.
  • Franklin Street Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 921 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Franklin Street Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.